383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Pablo Fernandez-Penas; Matteo Carlino; Katy Tsai; Victoria Atkinson; Monaster Shaheen; Sajeve Thomas; Catalin Mihalcioiu; Tom Van Hagen; Rachel Roberts-Thomson; Andrew Haydon; Andrew Mant; Marcus Butler; Gregory Daniels; Elizabeth Bunchbinder; John Hyngstrom; Mecker Moller; Igor Puzanov; C Lance Cowey; Eric Whitman; Carmen Ballesteros-Merino; Shawn Jensen; Bernard Fox; Emmett Schmidt; Scott Diede; Rebecca Setta; Jendy Sell; David Canton; Sandra Aung; Christopher Twitty; Sunny Xie; Ying Lu; Bridget O’Keefe; Alain Algazi; Adil Daud

doi:10.1136/jitc-2021-SITC2021.383

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password